DOT1L and ovarian cancer: Similar effects on ovarian cancer tumor growth in vivo in the xenograft model were observed with the administration of other DOT1L inhibitors, EPZ004777 (Fig. 3E, F) and DOT1L shRNA (Supplementary Fig. 6).